How to buy Virpax Pharmaceuticals stock (Virpax Pharmaceuticals)

Virpax Pharmaceuticals is a biotechnology business based in the US. Virpax Pharmaceuticals shares (VRPX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.33 – a decrease of 17.5% over the previous week. Virpax Pharmaceuticals employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Virpax Pharmaceuticals stock

Buy Virpax Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Virpax Pharmaceuticals stock price (NASDAQ: VRPX)

Use our graph to track the performance of VRPX stocks over time.

Virpax Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$0.33
52-week range	$0.29 - $5.48
50-day moving average more info button	$0.68
200-day moving average more info button	$1.83
Wall St. target price	$3.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-13.25

Is it a good time to buy Virpax Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Virpax Pharmaceuticals price performance over time

Historical closes compared with the close of $0.33 from 2024-12-20

1 week (2024-12-13)	-17.50%
1 month (2024-11-22)	-41.80%
3 months (2024-09-20)	-53.26%
6 months (2024-06-21)	-36.90%

1 year (2023-12-22)	-7.04%
2 years (2022-12-22)	-95.49%
3 years (2021-12-22)	39.1
5 years (2019-12-18)	N/A

Virpax Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-91.42%
Return on equity TTM	-362.29%
Profit margin	0%
Book value	$-0.99
Market Capitalization more info button	$3 million

TTM: trailing 12 months

Virpax Pharmaceuticals share dividends

We're not expecting Virpax Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Laboratory Corporation of America (LH.US) (1.27% forward annual dividend yield)
• Novartis AG ADR (NVS.US) (3.86% forward annual dividend yield)

Have Virpax Pharmaceuticals's shares ever split?

Virpax Pharmaceuticals's shares were split on a 1:10 basis on 29 February 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Virpax Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Virpax Pharmaceuticals shares which in turn could have impacted Virpax Pharmaceuticals's share price.

Virpax Pharmaceuticals share price volatility

Over the last 12 months, Virpax Pharmaceuticals's shares have ranged in value from as little as $0.286 up to $5.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Virpax Pharmaceuticals's is 1.095. This would suggest that Virpax Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Virpax Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Laboratory Corporation of America (LH.US): 1.036
• Novartis AG ADR (NVS.US): 0.505
• Teva Pharma Industries Ltd ADR (TEVA.US): 0.868

Virpax Pharmaceuticals overview

Virpax Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. .

Frequently asked questions

What percentage of Virpax Pharmaceuticals is owned by insiders or institutions?
Currently 2.572% of Virpax Pharmaceuticals shares are held by insiders and 0.037% by institutions. How many people work for Virpax Pharmaceuticals?
Latest data suggests 7 work at Virpax Pharmaceuticals. When does the fiscal year end for Virpax Pharmaceuticals?
Virpax Pharmaceuticals's fiscal year ends in December. Where is Virpax Pharmaceuticals based?
Virpax Pharmaceuticals's address is: 1055 Westlakes Drive, Berwyn, PA, United States, 19312 What is Virpax Pharmaceuticals's ISIN number?
Virpax Pharmaceuticals's international securities identification number is: US9282511073